New radiation therapy shows promise for Hard-to-Treat gut cancers

NCT ID NCT07404176

Recruiting now Disease control Sponsor: Tata Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a new radioactive drug called Terbium-161 DOTATATE in 20 people with advanced neuroendocrine tumors that have spread and stopped responding to standard treatment. The drug delivers radiation directly to cancer cells, aiming to control the disease with fewer side effects. Researchers will measure how well it shrinks or stabilizes tumors and monitor safety through blood tests and scans.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Terbium-161 DOTATATE (a radioactive drug that targets cancer cells)
What this could lead to: If successful, this could offer a new treatment option for patients with neuroendocrine tumors that no longer respond to current therapies, potentially with fewer side effects.
What could go wrong: This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The drug is experimental, and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system neuroendocrine tumor, grade 1/2 neoplasm neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NEUROENDOCRINE TUMORS NEUROENDOCRINE NEOPLASMS (TUMOURS) NEUROENDOCRINE TUMORS

Contacts and locations

Locations

Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
RECRUITING

Navi Mumbai, Maharashtra, 410210, India
Tata Memorial Hospital, Mumbai, India
RECRUITING

Mumbai, Maharashtra, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.